Menu
Search
|

Menu

Close
X

BioCryst Pharmaceuticals Inc BCRX.OQ (NASDAQ Stock Exchange Global Select Market)

3.46 USD
-- (--)
As of Jul 17
Previous Close 3.46
Open --
Volume --
3m Avg Volume 511,409
Today’s High --
Today’s Low --
52 Week High 9.94
52 Week Low 2.81
Shares Outstanding (mil) 110.31
Market Capitalization (mil) 381.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY19
6
FY18
21
FY17
25
FY16
26
EPS (USD)
FY19
-0.282
FY18
-0.979
FY17
-0.779
FY16
-0.749
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
16.92
8.16
Price to Book (MRQ)
vs sector
16.95
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
367.60
18.17
LT Debt to Equity (MRQ)
vs sector
237.73
13.01
Return on Investment (TTM)
vs sector
-136.54
12.64
Return on Equity (TTM)
vs sector
-251.96
17.19

EXECUTIVE LEADERSHIP

Robert Ingram
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Jon Stonehouse
President, Chief Executive Officer, Director, Since 2007
Salary: $550,000.00
Bonus: $325,188.00
Thomas Staab
Senior Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer, Since 2018
Salary: $449,203.00
Bonus: $193,157.00
Yarlagadda Babu
Senior Vice President - Drug Discovery, Since 2013
Salary: $420,000.00
Bonus: $180,600.00
William Sheridan
Senior Vice President, Chief Medical Officer, Since 2008
Salary: $485,574.00
Bonus: $208,797.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4505 Emperor Blvd Ste 200
DURHAM   NC   27703-8457

Phone: +1919.8591302

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

SPONSORED STORIES